Clinical trials
Macular Degeneration clinical trials
Below are recruiting macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 168 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07053358RecruitingEarly Phase 1
Gene therapy for wet AMD
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
ShanghaiAges 50 years+ - NCT07189169RecruitingPhase 3
Testing QA108 for intermediate AMD
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
BeijingAges 45–85 - NCT06718816Recruiting
Long-term follow-up of AL-001 eye injection for wet AMD
This trial is a long-term follow-up for people who already received the AL-001 eye injection for wet age-related macular degeneration (wet AMD) in an earlier study. It will check how you are doing over time.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07582042Recruiting
Vision testing in geographic atrophy treated with pegcetacoplan
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Salt Lake City, UtahAges 65–90 - NCT06492863RecruitingPhase 1/Phase 2
Gene therapy (FT-003) for wet AMD
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
Tianjin, Tianjin,ChinaAges 50–80 - NCT07275840RecruitingPhase 2
Testing IBI302 for wet age-related macular degeneration
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
Shanghai, Shanghai MunicipalityAges 50 years+ - NCT07392255RecruitingPhase 1/Phase 2
Testing CTx001 for geographic atrophy (GA) in AMD
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Carmel, IndianaAges 55 years+ - NCT03683251RecruitingPhase 3
Extension study for a refillable eye implant plus ranibizumab
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Phoenix, ArizonaAges 50 years+ - NCT05210803Enrolling by invitationPhase 2
Long-term safety follow-up for wet AMD treatment
This study is a follow-up for people who have already received an injection of RGX-314 for wet age-related macular degeneration (AMD) in an earlier trial. It looks at how the treatment works over a longer time and any long-term effects.
Phoenix, ArizonaAges Any age - NCT06990269RecruitingPhase 2
Study of ADX-038 for geographic atrophy in dry AMD
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Gilbert, ArizonaAges 60 years+ - NCT06165068RecruitingPhase 3
Antiplatelet and antioxidant drugs for dry AMD with drusen
This study tests whether antiplatelet drugs (like aspirin) and antioxidants can slow the growth of drusen (yellow deposits) in dry age-related macular degeneration (AMD). It may help prevent the disease from worsening.
Bangkok, DusitAges 50–85 - NCT07005323Recruiting
New treatment for resistant wet AMD
This trial tests a new treatment for people with a hard-to-treat form of wet age-related macular degeneration (AMD) that has not improved with standard anti-VEGF injections. It aims to stop the disease from getting worse and possibly improve vision.
Ube, YmaguchiAges 50–85 - NCT07144137Recruiting
Observation study for geographic atrophy progression
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
Mountain View, CaliforniaAges 55 years+ - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Gilbert, ArizonaAges 55 years+ - NCT03752840Recruiting
Community eye-worker program in Nepal
This trial tests a village-based approach to bring eye care closer to older community members. If you live in the right area and are willing to participate, it may help improve access to eye screening and services.
San Francisco, CaliforniaAges 60 years+ - NCT03921931Recruiting
Test retinal responses to light in healthy eyes or eye disease
This is a small pilot study that measures how parts of the retina change before and after light stimulation. It may help researchers understand eye function in people with normal vision or specific eye conditions like glaucoma or dry age-related macular degeneration (AMD).
Vienna, State of ViennaAges 18 years+ - NCT04008121RecruitingEarly Phase 1
Testing an eye imaging drug during retinal blood-vessel photos
This early safety study tests how well and how safely an investigational dye (MB-102) works during a special eye imaging test of retinal and choroidal blood vessels. It compares it to the commonly used fluorescein dye and may help doctors refine future eye imaging approaches.
Ann Arbor, MichiganAges 18 years+ - NCT04292080RecruitingPhase 2
Tecfidera trial to slow worsening geographic atrophy
This Phase 2 study tests dimethyl fumarate (Tecfidera) to slow the growth of geographic atrophy, a form of age-related macular degeneration that affects central vision. You may be asked to take the study medicine and attend regular eye scans over about 2 years to see if it helps.
Créteil, Val De MarneAges 55–85 - NCT04697095Recruiting
Testing immune cells from specific AMD eye types
This study collects immune cells (from a blood sample) from people with certain types of age-related macular degeneration (AMD) and compares how long they live. It may help researchers understand how immune-related changes relate to AMD outcomes.
LyonAges 15 years+ - NCT05093374RecruitingPhase 4
AI-guided care for wet age-related macular degeneration
This Phase 4 study tests an artificial-intelligence (AI) system used in real-world care for people with “wet” age-related macular degeneration. The goal is to help doctors monitor and treat the eye more accurately and safely over time.
Vienna, State of ViennaAges 50–100 - NCT05147701RecruitingPhase 1
Testing stem cell treatment for NAION safety
This Phase 1 study tests whether lab-made stem cells taken from donated umbilical cord are safe for people with NAION. It mainly looks for side effects and safety rather than proving the treatment works.
St John'sAges Any age - NCT05438732Recruiting
Test of an implanted eye device plus vision training for AMD
This study tests a device that is surgically implanted in the eye of people with late-stage age-related macular degeneration (AMD). It also uses vision training with a telescope-like tool to see if the treatment can improve day-to-day vision.
Loma Linda, CaliforniaAges 65 years+ - NCT05465252Recruiting
Omega-3 supplement to slow early dry macular degeneration
This trial studies whether taking omega-3 fatty acids can slow the worsening of dry age-related macular degeneration (AMD) in people with early or intermediate disease. It may help by testing if omega-3 changes how the retina changes over time.
ShanghaiAges 50–85 - NCT05626114RecruitingPhase 2
Study of a lab-made eye treatment after subretinal surgery
This Phase 2 study tests OpRegen, a treatment delivered during special eye surgery, for geographic atrophy related to age-related macular degeneration (GA from AMD). It also includes an imaging “substudy” that uses detailed pictures of your retina to better track safety and activity.
Beverly Hills, CaliforniaAges 50 years+
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for macular degeneration?
- Yes. Clin2 currently lists 168 recruiting macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.